compani
strong aid legaci brand
report result our/con estim top-line non-gaap ep came
est y/i respect
midpoint guidanc rais driven beat ciali
trulic humalog partial off-set fx base trend rais
estim notabl humalog verzenio partial off-set lower jardianc
tradjenta decreas global jardianc sale book
reflect new assumpt flat us price trend net
impact estim chang revis outlook termin growth rate
increas po spite favor
result major strength driven legaci product limit upsid
jardianc price trend warrant monitor reiter neutral
notabl updat jardianc miss our/street jardianc forecast
respect driven lower realiz price management cite one-tim
factor includ adjust rebates/discount indic lower us growth
normal basi vs actual revis us jardianc assum flat us
price sale compound-annual-growth-rate driven categori growth continu market
share gain view main risk est go forward favor result
azn declar trial read could reduc peak jardianc share
diabet move late earli base
strength data competit posit lli vs market
unclear data remain in-hous management indic data
present easd oct note data met high bar advanc
includ better hemoglobin weight loss rel current glp rewind
trial top-line data remain track management re-affirmed view longer trial
durat yr vs yr nvo leader enabl studi accru suffici
event broad less enrich popul elanco spin lli anim health spin
includ ipo share made avail new exist sharehold
mechan distribut remain share still consider
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
timestamp juli edtcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani juli
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough bogey
net interest incom
fx rate guidanc
compani juli
compani
price object po base blend averag discount
cash flow dcf target multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani juli
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani juli
